As far as I can tell AHZ is now a research and development company that just sold the rights to its premiere IP outright with a small royalty. If the company could dump the majority of its staff and focus on IP generation for a few years this would be fine. But it can’t, it still has to manufacture these patches. So the entire manufacturing staff is being kept on. No idea whAt that equates to per year, but the cash burn on this company is prodigious and always has been. And also it’s major problem.
this has still not been solved. Now is time for
another code red that actually trims the fat this time.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-140
-
- There are more pages in this discussion • 150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |